Bristol-Myers Squibb Shows Strong Fundamentals in Guru Report

Bristol-Myers Squibb Co shows promise with an 87% rating in a multi-factor investment strategy report, indicating strong fundamentals. Investors may view this as a positive signal for stock performance.

Date: 07-03-2025

AI Rating: 7

Positive Ratings Indicate Strong Fundamentals

Bristol-Myers Squibb Co (BMY) has received a high rating of 87% from the Multi-Factor Investor model. This model is designed to identify low volatility stocks with strong momentum and high net payout yields.

According to the report, several key metrics pass this investment strategy. The strong rating suggests that the company is viewed positively, particularly in terms of its fundamentals and valuation.

BMY is categorized as a large-cap value stock within the Biotechnology & Drugs industry. A rating of 80% or higher typically indicates some interest from the strategy, while a rating above 90% signals strong interest. With BMY at 87%, it falls into a category of moderate to strong interest, which may attract further investor attention.

The report highlights various criteria tested as part of this strategy:

Market Cap: PASS
Standard Deviation: PASS
Twelve Minus One Momentum: NEUTRAL
Net Payout Yield: NEUTRAL
Final Rank: PASS

The passing scores on Market Cap and Standard Deviation imply that BMY is stable in terms of size and volatility, which can be attractive metrics for investors looking for safety alongside growth.

This report does not provide specific information regarding Earnings Per Share (EPS), Revenue Growth, Net Income, Profit Margins, Free Cash Flow, or Return on Equity, therefore these areas were not analyzed further. Nonetheless, the overall sentiment derived from the high rating supports a favorable outlook for BMY as a stock worth considering for investment.

Stocks: BMY